EP0674627A1 - Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors - Google Patents

Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors

Info

Publication number
EP0674627A1
EP0674627A1 EP94902868A EP94902868A EP0674627A1 EP 0674627 A1 EP0674627 A1 EP 0674627A1 EP 94902868 A EP94902868 A EP 94902868A EP 94902868 A EP94902868 A EP 94902868A EP 0674627 A1 EP0674627 A1 EP 0674627A1
Authority
EP
European Patent Office
Prior art keywords
pyrimidine
diamino
compound
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94902868A
Other languages
German (de)
French (fr)
Inventor
Eric Cleveland Bigham
John Frederick Reinhard, Jr.
Philip Keith Moore
Rachel Cecilia Babbedge
Richard Graham Wellcome Foundation Ltd. Knowles
Malcolm Stuart The Wellcome Foundation Ltd Nobbs
Donald The Wellcome Foundation Ltd. Bull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929226377A external-priority patent/GB9226377D0/en
Priority claimed from GB939303221A external-priority patent/GB9303221D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0674627A1 publication Critical patent/EP0674627A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to neuronal nitric oxide (NO) synthase inhibitors, to methods for their manufacture, to pharmaceutical compositions containing them and to their use in therapy, in particular their use in diseases of the nervous system in which NO plays a part.
  • NO neuronal nitric oxide
  • endothelium-derived relaxing factor a labile humoral factor termed endothelium-derived relaxing factor (EDRF).
  • NO nitric oxide
  • NO is the active component of amyl nitrite, glyceryl trinitrite and other nitro vasodilators.
  • EDRF endothelium-derived relaxing factor
  • NO is the endogenous stimulator of the soluble guanylate cyclase and is involved in a number of biological actions in addition to endothelium-dependent relaxation including cytotoxicity of phagocytic cells and cell-to-cell communication in the central nervous system (see Moncada et al, Biochemical Pharmacology, 23., 1709-1715 (1989) and Moncada et a], Pharmacological Reviews, 42, 109-142 (1991)). It is now thought that excess NO production may be involved in a number of conditions, particularly conditions which involve systemic hypotension such as toxic shock and therapy with certain cytokines.
  • neuronal NO synthase is a distinct protein from the endothelial NO synthase (Sessa et al, J.Biol.Chem.. 267, 15274-15276. 1992).
  • NO synthesis plays an important part in the pathology of a range of diseases of the nervous system, eg. ischemia.
  • non-selective inhibitors of NO syntheses cause profound changes in blood pressure and blood flow, including cerebral blood flow.
  • ischemic injury inherently reduces the blood supply to the brain and any further decrease in blood flow caused by a non-selective NO synthase inhibitor would have a deleterious effect, potentially opposing any beneficial effect of decreased NO production within the brain.
  • studies of middle cerebral artery occlusion in both rats and mice have demonstrated a substantial protection effect of low doses of NO synthase inhibitors (see for example Nowicki et al. Eur. J.Pharmacol.. 1991 , 204.
  • L-NMMA L-arginine analogue L-N- monomethyl-arginine
  • L-NMMA L-N- monomethyl-arginine
  • the therapeutic use of certain other NO synthase inhibitors apart from L- NMMA for the same purpose has also been proposed in WO 91/04024 and in EP-A- 0446699.
  • Compounds like L-NMMA do not show selectivity for the neuronal NO synthase as opposed to the other NO synthases.
  • tetrahydrobiopterin (6R)-5,6,7,8-tetrahydro-L-biopterin (hereinafter tetrahydrobiopterin) is necessary for activity of the NO synthase enzymes.
  • tetrahydrobiopterin causes expression of the activity of the enzymes by binding to them.
  • compounds which competitively bind at the tetrahydrobiopterin sites of NO synthases inhibit neuronal NO synthase selectively over endothelial NO synthase.
  • the present invention provides the use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase.
  • the present invention provides a method for the treatment or prophylaxis of a condition where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase which comprises the administration of an effective amount of a compound which binds at the tetrahydrobiopterin site of NO synthase.
  • Suitable compounds which bind at the tetrahydrobiopterin site include those of formula (IA), formula (IC) or structural analogues of tetrahydrobiopterin and or salts thereof, as hereinafter defined.
  • R ⁇ and R ⁇ are the same or different and each is hydrogen or a C ⁇ __ alkyl group or NR--R2 forms a 5- or 6-membered heterocvclic ⁇ roup — NJ ⁇ , 'T ⁇ ⁇ T wherein
  • T is oxygen.
  • D is a group S(O) x wherein x is 0, 1 or 2, a C 1.4 alkylene chain, or a C2.4 alkenylene or alkynylene chain; d is 0 or 1 ;
  • Ar is a monocyclic or bicyclic ring system which may contain one or two heteroatoms and which contains at least one aromatic ring;
  • R- represents hydrogen or one to three substituents on the ring system Ar which may be the same or different and are chosen from halo, NR- ⁇ R ⁇ wherein R? and R ⁇ are independently selected from hydrogen or S(O) x > R wherein x' is 0, 1 or 2 and R ⁇ is Cj_4 alkyl; nitro, cyano.
  • a C1.4 carboxcylic acid group or an ester thereof C ⁇ __ alkyl optionally substituted by one to three halo atoms
  • R ⁇ is hydrogen, C ⁇ __ alkyl, hydroxy, halo, trifluoromethyl or a group NRIORI * wherein R ⁇ and R-- 1 are the same or different and each is hydrogen or Cj_4 alkyl, or NRI ORI I forms a 5- or 6- membered heterocyclic group optionally substituted by a C ⁇ __ alkyl group or R ⁇ represents a C _2 alkylene group linking
  • Preferred heterocyclic groups include morpholino, piperidino and methylpiperazino.
  • R * * ,R- *** ,X,Y,R4 are as hereinbefore defined
  • Ar' is a monocyclic or bicyclic ring system containing at least one aromatic ring
  • R**-' represents hydrogen or one to three substituents which may be the same or different and are chosen from halo, amino, nitro, cyano.
  • a C1.4 carboxylic acid group or an ester thereof a group -(A) m R° wherein A and m are as hereinbefore defined and R***' is C 1.4 alkyl optionally substituted by halo;
  • Preferred compounds of the formula (I A) include those of the formula (III)
  • d is 0;
  • Ar is phenyl, naphthyl, tetrahydronaphthyl, or benzothienyl.
  • Ar is phenyl
  • R**- 1 is halo, most suitably chloro or bromo, C1.4 alkyl or C 1.4 alkoxy, preferably methoxy.
  • Ar is phenyl the. or one of the. subsituents is at the 4-position of the phenyl ring.
  • R-* and R ⁇ are hydrogen, methyl, ethyl or NR--R**-- is a methyl-piperazino group.
  • R* 1 and R- are hydrogen.
  • R4 is most suitably hydrogen or NEb and preferably R ⁇ is hydrogen.
  • Y is preferably CNH2
  • Suitable compounds of the formula (IA) include
  • Preferred compounds of the formula (IA) include:
  • R ⁇ , R ⁇ , Rl5 a ⁇ j R16 ⁇ Q eac h separately selected from hydrogen, halo, haloalkyl, formyl, carboxy, sulpho, cyano, nitro, COR --8 and + NR18R19 20 ?
  • R 1 ⁇ , R 9 and R-® are each separately alkyl, aralkyl or aryl groups and R-* ⁇ is selected form hydrogen, halo, haloalkyl, formyl, carboxy, sulpho, cyano, nitro, hydroxy, alkoxy, alkyl, COR18, NHCOR 18 and +NR18R19R20 groupSj wherein R 18 5 R 19 and R2° are each separately alkyl aralkyl or aryl groups.
  • the halo and haloalkyl groups may for example be a fluoro, bromo, iodo or particularly a chloro group or a C ⁇ _i2 > particularly C ⁇ _ ⁇ , straight or branched chain alkyl group, for example an ethyl or especially a methyl group, substituted by one or more, for example three, such halo groups.
  • Aralkyl and aryl groups R * • **, Rl9 and R20 may conveniently be or contain various forms of aromatic hydrocarbyl group but 1- or 2-naphthyl and particularly phenyl groups are of most interest.
  • Alkyl and aralkyl group R** ** - * , Rl9 and R****0 may conveniently be or contain alkyl group such as are described above in relation to the haloalkyl groups R ⁇ , R ⁇ , R-*- ⁇ Rl6.
  • each of the groups R-* 3 , R-* 4 , R**- 5 and R-* ⁇ may be hydrogen it is preferred that at least one is other than hydrogen, particularly the group R-* 4 or R*-5 or especially R-* 3 , although preferably two or three of R 3 , R* , R***** and Rl° " are hydrogen.
  • the groups which are other than hydrogen are those which effect a significant degree of electron withdrawal from the benzene ring. Accordingly a nitro group is of particular interest.
  • Other groups of interest, possibly together with another type of group such as nitro, are haloalkyl and especially halo groups.
  • R ⁇ , R-* 4 , R! *** and R1 ° " is other than hydrogen the two or more substituents may differ from each other. Conveniently however at least one. for example R ⁇ 3 , is one of the groups just indicated as being of interest.
  • R ⁇ 7 may be other than hydrogen, for example a halo group such as chloro. it is preferably hydrogen.
  • R* 3 , R ⁇ 4 , R ⁇ or R--6 when one or more of R* 3 , R ⁇ 4 , R ⁇ or R--6 is a group + NR1 R-* R 0 the compounds will be a quaternary ammonium salt which contains one or more physiologically acceptable anions.
  • anions may for example correspond to those present in the acid addition salts hereinafter described but halo groups such as chloro and bromo are preferred.
  • the physiologically acceptable salt may be one formed with a suitable base, examples of which are the alkali metal hydroxides, for example sodium hydroxide, quaternary ammonium hydroxides and amines such as tris (tris representing 2-amino-2- hydroxymethyl propane 1.3-diol).
  • the indazoles (IC) can be used in the form of physiologically acceptable ester.
  • esters may be formed respectively with a suitable phenol or alcohol or with a suitable organic acid or even inorganic acid.
  • indazoles (IC) of use in the present invention are indazole and its 4-, 5-, 6- and 7-nitro derivatives together with their halogeno, for example chloro or bromo, analogues.
  • halogeno for example chloro or bromo, analogues.
  • nitro derivatives especially 7- nitroindazole, are of particular interest.
  • the compounds of formula (IA) (IB) and (IC) may include a number of asymmetric centres in the molecule depending on the precise meaning of the various groups and formula (IA) (IB) and (IC) are intended to include all possible isomers.
  • the activity of a compound as a tetrahydrobiopterin-site inhibitor of neuronal NO synthase can be determined by an assay in which L-[-* C]-arginine is convened to [U ⁇ 4 C]-citrulline by brain cytosol NO synthase (as described by Salter et al., FEBS Lett. 221, 1991 , 145-149) following a preincubation with the compound in the absence or presence of a saturating concentration (typically lO ⁇ M) of tetrahydrobiopterin).
  • a saturating concentration typically lO ⁇ M
  • Such inhibitors also show activity in an intact cell system in which conversion of [ ⁇ 4 C]-L-arginine to [ ⁇ 4 C]-citrulline is measured in brain slices stimulated with veratrine.
  • single coronal slices of adult rat forebrain are preincubated in Krebs-Henseleit buffer before transfer to fresh buffer containing L-[U- ⁇ 4 C]-arginine. lO ⁇ g/ml veratrine and various concentrations of test compound (routinely 1- lOO ⁇ M). The mixture of test compound and coronal slices is then incubated and the level of [U--* 4 C]-citrulline formed, then determined (essentially as described-previously, Salter et al 1991).
  • Selectively for the neuronal NO synthase can be determined by comparison with enzyme assays for other forms of NO synthase or by comparisons with intact cell preparation NO synthesis such as in rat aortic rings in which the basal tone of the tissue is used as an indication of the activity of the constitutive NO synthase.
  • the activity of the compounds can be determined by the method of Dwyer et al, Biochem. Biophys. Res. Commun. 1991. 176. 1 136-1 141.
  • SUBSTITUTE SHEET Conditions in which there is an advantage in selectively inhibiting neuronal NO production include cerebral ischemia, CNS trauma, epilepsy, AIDS dementia, chronic neurodegenerative disease (eg Parkinson's disease), schizophrenia and chronic pain, and conditions in which non-adreneric non-cholinergic nerve may be implicated such as priapism. obesity and hyperphagia. They are also suitable for use as analgesics and in the treatment of acute neurodegenerative diseases, for example in the treatment of convulsions or particularly for prophylactic use in the prevention of an ischemic incident and possibly also in memory enhancement.
  • treatment of a patient is intended to include prophylaxis.
  • the present invention includes neuronal NO inhibitors in the form of salts, in particular acid addition salts.
  • Suitable salts include those formed with both organic and inorganic acids.
  • Such acid addition salts will normally be pharmaceutically acceptable although salts of non- pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question.
  • preferred salts include those formed from hydrochloric, hydrobromic.
  • Salts of neuronal NO inhibitors can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.
  • Esters are pharmaceutically acceptable esters, for example C1.4 alkyl esters.
  • a further aspect of the present invention provides a compound of formula (IA), (IB) or (IC) or a salt thereof for use in medicine, with the proviso that R 2 i s not hydrogen, and that R-* 4 and R--5 are not independently selected from hydrogen, nitro or carboxy when R-* 3 , R ⁇ ⁇ and R ⁇ are each hydrogen.
  • novel compounds of formula (IA) and salts thereof include:
  • the neuronal NO synthase inhibitors of the present invention Whilst it may be possible for the neuronal NO synthase inhibitors of the present invention to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation.
  • the present invention provides a pharmaceutical formulation comprising a compound which binds at the tetrahydrobiopterin site of NO Synthase in combination with a pharmaceutically acceptable carrier therefor and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (IA), (IB) or (IC) or a pharmaceutically acceptable salt or solvate thereof ("active ingredient”) with the carrier which constitutes one or more accessory ingredients.
  • active ingredient a pharmaceutically acceptable salt or solvate thereof
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration my be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient: as a powder or granules: as a solution or a suspension in an aqueous liquid or a non-aqueous liquid: or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water- for-injection, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration mav include flavourins aeents.
  • the neuronal NO synthase inhibitors of the invention may be administered orally or via injection at a dose of from 0J to 500mg/kg per day.
  • the dose range for adult humans is generally from 5mg to 35g/day and preferably 5mg to 2g/day.
  • Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5mg to 500mg, usually around lOmg to 200mg.
  • the neuronal NO synthase inhibitors of the invention are preferably administered orally or by injection (intramuscular, intravenous or subcutaneous).
  • injection intramuscular, intravenous or subcutaneous.
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration may vary depending on the condition and its severity.
  • the present invention also provides a process for the preparation of the novel compounds of formula (IA), (IB) and (IC) as hereinbefore defined
  • R21 is cyano or COR2 3 wherein R 3 is hydroxy, C1.4 alkoxy or hydrogen and R22 is oxo or a group C ⁇ H wherein L is a leaving group; with amino guanidine or guanidine respectively.
  • Suitable leaving groups include alkoxy and substituted secondary amino groups, eg. aniline and substituted aniline groups and heterocyclic amines such as morpholine.
  • the reaction conveniently takes place in a polar solvent, for example an alkanol. e.g. a C ] _4 alkanol such as ethanol. or a dipolar aprotic solvent such as
  • R and R2 are hydrogen the removal of one or more protecting groups from NR*R and optionally from R 4 , when it is desired that R 4 is NK .
  • Suitable protecting groups are derived from carboxylic acids, for example acetic or benzoic acids.
  • Suitable chlorinating agents include phosphorous oxychloride which can also be used as solvent.
  • the amination is conveniently carried out by reaction with ammonia in a suitable solvent such as a
  • reaction is suitably carried out at an elevated o temperature, for example 50-200 C. in a sealed system, and preferably under pressure.
  • This reaction is conveniently carried out in the presence of a catalyst, for example a palladium catalyst.
  • a catalyst for example a palladium catalyst.
  • tetrakistriphenylphosphine palladium is a suitable catalvst for this reaction.
  • the reaction is convenientlv carried out at a non- o o o o extreme temperature, for example 20 to 100 C and preferably 50 to 90 C in a solvent, for example a mixture of an aromatic hydrocarbon such as benzene and an alkanol such as ethanol under ⁇ in inert atmosphere.
  • Acyl groups for example acetyl groups, are suitable protecting groups when R-* ⁇ and/or R b are hydrogen.
  • Compounds of the formula (IB) may be prepared by the reduction of the corresponding 8-oxide. This is conveniently accomplished by hydrogenation in the presence of a suitable catalyst.
  • the catalyst will normally be a transition metal catalyst, for example containing palladium or platinum, and will be chosen so that it reduces the 8-N-oxide function without affecting any of the other groups in the molecule, unless it is desired to also reduce these.
  • palladium for example containing palladium or platinum
  • a suitable selective catalyst (as a 5% of a mixture with barium sulphate) is a suitable selective catalyst.
  • the reaction is conveniently carried out in a solvent, for example a glacial acetic acid/trifluoroacetic acid mixture, at a non-extreme temperature, for example between o o
  • SUBSTITUTE SHEET The compounds may be prepared directly in salt form or converted thereto by reaction of the indazole with the appropriate acid or base. Esters may similarly be prepared directly or through acid or base. Esters may similarly be prepared directly or through reaction of the corresponding indazole containing a carboxy or sulpho group with the appropriate alcohol or of the corresponding indazole containing a hydroxy group with the appropriate acid.
  • the present invention also provides a novel process for the preparation of a compound of formula (IA) as hereinbefore defined, which comprises the reaction of a compound of formula (VII).
  • R 3 -Ar-(D) c j-B(OH)2 wherein R-*, R2, R 3 , R 4 , Ar, D, d, X and Y are as hereinbefore defined, followed by deprotection if necessary.
  • d is 0 and/or Ar is phenyl.
  • the reaction is conveniently carried out in a polar solvent, for example toluene, in the presence of aqueous sodium carbonate and tetrakistriphenylphosphine palladium, under an inert atmosphere, for example nitrogen.
  • a polar solvent for example toluene
  • aqueous sodium carbonate and tetrakistriphenylphosphine palladium under an inert atmosphere, for example nitrogen.
  • the reaction is preferably carried out at a non- extreme temperature of 20°C to 150°C, suitably 80°C to 120°C.
  • R*, R , R 4 , X and Y are as hereinbefore defined, by reaction with iodine monochloride.
  • the reaction is carried out in a suitable solvent, such as glacial acetic acid, at non-extreme temperature for example room temperature.
  • the above product was divided into three equal portions. These were placed in separate Young tubes, methvl iodide (l. ⁇ gms) and DMF/18mls) added to each, and o the tubes sealed. After stirring at 50 C for 4 hours the contents were cooled, combined, and the solvent removed in vacuo. The residue was then partitioned between ethyl acetate and water, and the organic phase again washed with water before drvin ⁇ over MgSO . After treating with activated charcoal, the solvent was
  • the chloroform layer was washed once with saturated sodium bicarbonate, twice with water and dried over anhydrous magnesium sulphate. The solvent was removed under vacuo and the crude product was purified by column chromatography (Si ⁇ 2) eluting with chloroform to 2% methanol-chloroform.
  • 2,6-Diacetamido-3-(3,5-dichlorophenyl)pyridine was suspended in dilute hydrochloric acid (0.40ml, 12M HCl/lml H2O) and refluxed at 120°C for 1.50 hours.
  • the reaction mixture was cooled in an ice-bath and basified with 0.880 ammonia.
  • the white solid which precipitated was filtered, washed with water and dried under vacuo at room temperature.
  • the crude product was purified by column chromatography [SiO?] elutin ⁇ with ether.
  • the product was triturated with o petroleum ether, filtered and dried under vacuo at 70 C to give a cream solid.
  • the title compound was prepared from 3-amino-6-chloromethyl- 2-pyrazinecarbonitrile 4-oxide and 4-chlorophenethanol by the method of Bigham et al, J.Med.Chem. 1987, 3 ⁇ , 40-45.
  • the activity of a compound as a tetrahydrobiopterin-site inhibitor of neuronal NO synthase was determined by an assay in which L-[U-- 4 C]-arginine is convened to [U*- 4 C]-citrulline by brain cytosol NO synthase (as described by Salter M. Knowles. R.G. and Moncada, S. (1991) FEBS Lett. 291, 145-149. following a 5 min preincubation with the compound in the absence or presence of a saturating concentration (typically lO ⁇ M) of tetrahydrobiopterin).
  • a saturating concentration typically lO ⁇ M
  • Nitric oxide synthase (NOS) activity was determined in vitro by the method of Dwyer et al., Biochem. Biophys. Res. Commun. 1991. 176, 1 136-1 141. Mice (male. LACA, 28-32 g) were killed by cervical dislocation. Cerebella were removed, homogenized (1 :10 w/v in 20mM tris buffer containing 2mM EDTA, pH. 7.4) and aliquots (25 ⁇ l) incubated (37°C) with L-arginine (120nM) containing 0.5 ⁇ Ci [ 3 H]- arginine (specific activity 62 Ci mmol"-*), NADPH (0.5mM) and CaCb (0.75mM).
  • Incubations also contained (a) 7-nitroindazole (MIM Research Chemicals Ltd.) in 0.5% w/v sodium carbonate solution (dissolution was effected by heating to 80°C and cooling when the 7-nitroindazole remained in solution), (b) for comparative puposes.
  • mice were injected i.p. with 7-nitroindazole (25 mg kg"-*) or L- NAME (50mg kg"-*) and killed 15 minutes thereafter. Cerebella were removed, homogenized and NOS activity determined as described above.
  • Anti-nociceptive activity of 7-nitroindazole (10-50 mg kg "') administered i.p. to mice as a suspension in arachis oil produced by sonication was determined by the formalin-induced hindpaw licking assay as descrived by Moore et al., British Journal of Pharmacology, 1991, 102, 198-202. Control animals received 10ml kg'-- of arachis oil or saline (0.9% w/v NaCl). This test shows hindpaw licking time (seconds) in the early (0-5 minutes) and late (15-30 minutes) phases on injection of lO ⁇ l formalin (5% v/v) administered 15 minutes after the 7-nitroindazole.
  • the ED50 for the anti-nociceptive effect was 26 mg kg"' (equivalent to 159.5 ⁇ mol kg"').
  • Example 7 The procedure of Example 7 was repeated for 7-nitroindazole and other indazoles but using rat cerebella.
  • the IC50 values so obtained for inhibition of rat cerebella nitric oxide synthase (NOS) for various indazoles are shown in Table 2 below.
  • Example 8 The procedure of Example 8 was repeated for 7-nitroindazole and other indazoles.
  • the percentage inhibition of formalin-induced licking in the late phase following the administration of 50 mg kg"' i.p. of the indazoles is shown in Table 2 below.
  • Table 2 For the compound 5-nitroindazole. where an asterisk is shown, a pronounced sedative effect was produced which interfered with the determination of the anti-nociceptive effect so that it could not be quantitated.
  • the other indazoles did not exhibit an overtly sedative effect.
  • the 7-nitroindazole is mixed with 'Avicel' and polyvinylpyrrolidone is added, dissolved in sufficient industrial methylated spirits (74° OP) to produce a mass suitable for granulating.
  • the mass is granulated through a 20 mesh sieve and the resultant granules are dried at a temperature not exceeding 50°C.
  • the dried granules are passed through a 20 mesh sieve and the alginic acid and magnesium stearate are then added and mixed with the granules.
  • the produce is compressed into tablets each weighing 300 mg on 3/8 inch flat bevelled edge divided punches.
  • the tablets are prepared by essentially the same procedure as described in (A) and are compressed at a tablet weight of 400mg on 7/16 inch fait bevelled punches.
  • the 7-nitroindazole is mixed with lactose and half the total quantity of maize starch required, and a 5% solution of gelatine in water is added to the mass.
  • the product is granulated through a 16 mesh sieve, and the resultant granules are dried to constant weight
  • SUBSTITUTE SHEET at a temperature not exceeding 50°C.
  • the dried granules are passed through a 20 mesh sieve and mixed with magnesium stearate and the remainder of the maize starch.
  • the product is compressed at a 300 mg tablet weight on 3/8 inch flat bevelled edge divided punches.

Abstract

The use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the treatment of conditions where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase is disclosed. Pharmaceutical formulations comprising such compounds, and processes, including a novel process, for their preparation are also disclosed.

Description

PYRIMIDINE, PYRIDINE , PTERIDINONE AND INDAZOLE DERIVATIVES AS ENZYME INHIBITORS
The present invention relates to neuronal nitric oxide (NO) synthase inhibitors, to methods for their manufacture, to pharmaceutical compositions containing them and to their use in therapy, in particular their use in diseases of the nervous system in which NO plays a part.
It has been known since the early 1980's that the vascular relaxation brought about by acetylcholine is dependent on the presence of the endothelium and this activity was ascribed to a labile humoral factor termed endothelium-derived relaxing factor (EDRF). The activity of nitric oxide (NO) as a vasodilator has been known for well over 100 years and NO is the active component of amyl nitrite, glyceryl trinitrite and other nitro vasodilators. The recent identification of EDRF as NO has coincided with the discovery of a biochemical pathway by which NO is synthesised from the amino acid L-arginine by the enzyme NO synthase.
NO is the endogenous stimulator of the soluble guanylate cyclase and is involved in a number of biological actions in addition to endothelium-dependent relaxation including cytotoxicity of phagocytic cells and cell-to-cell communication in the central nervous system (see Moncada et al, Biochemical Pharmacology, 23., 1709-1715 (1989) and Moncada et a], Pharmacological Reviews, 42, 109-142 (1991)). It is now thought that excess NO production may be involved in a number of conditions, particularly conditions which involve systemic hypotension such as toxic shock and therapy with certain cytokines.
It has recently become apparent that the neuronal NO synthase is a distinct protein from the endothelial NO synthase (Sessa et al, J.Biol.Chem.. 267, 15274-15276. 1992).
We believe that NO synthesis plays an important part in the pathology of a range of diseases of the nervous system, eg. ischemia. However, non-selective inhibitors of NO syntheses cause profound changes in blood pressure and blood flow, including cerebral blood flow. Unfortunately, ischemic injury inherently reduces the blood supply to the brain and any further decrease in blood flow caused by a non-selective NO synthase inhibitor would have a deleterious effect, potentially opposing any beneficial effect of decreased NO production within the brain. Nevertheless, studies of middle cerebral artery occlusion in both rats and mice have demonstrated a substantial protection effect of low doses of NO synthase inhibitors (see for example Nowicki et al. Eur. J.Pharmacol.. 1991 , 204. 339-340). At high doses, or in models of global ischemia, these inhibitors fail to provide protection. Thus. there is a need for a potent inhibitor of neuronal NO synthase with preferably little or no activity against the vascular endothelial NO synthase.
The synthesis of NO from L-arginine can be inhibited by the L-arginine analogue L-N- monomethyl-arginine (L-NMMA) and the therapeutic use of L-NMMA for the treatment of toxic shock and other types of systemic hypotension has been proposed (WO 91/04024 and GB-A-2240041). The therapeutic use of certain other NO synthase inhibitors apart from L- NMMA for the same purpose has also been proposed in WO 91/04024 and in EP-A- 0446699. Compounds like L-NMMA do not show selectivity for the neuronal NO synthase as opposed to the other NO synthases.
It is known that the presence of (6R)-5,6,7,8-tetrahydro-L-biopterin (hereinafter tetrahydrobiopterin) is necessary for activity of the NO synthase enzymes. We believe that tetrahydrobiopterin causes expression of the activity of the enzymes by binding to them. We have now found that compounds which competitively bind at the tetrahydrobiopterin sites of NO synthases inhibit neuronal NO synthase selectively over endothelial NO synthase.
Accordingly, the present invention provides the use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase.
In another aspect, the present invention provides a method for the treatment or prophylaxis of a condition where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase which comprises the administration of an effective amount of a compound which binds at the tetrahydrobiopterin site of NO synthase.
Suitable compounds which bind at the tetrahydrobiopterin site include those of formula (IA), formula (IC) or structural analogues of tetrahydrobiopterin and or salts thereof, as hereinafter defined.
SUBSTITUTE SHEET Wherein R^ and R~ are the same or different and each is hydrogen or a C \__ alkyl group or NR--R2 forms a 5- or 6-membered heterocvclic εroup — NJ ^, 'T^ ^T wherein
T is oxygen. CFb or nitrogen substituted by hydrogen or C 1.4 alkyl. and v and w are the same or different and each is 1 or 2 provided the sum of v and w is 3 or 4; X is nitrogen or CH; Y is nitrogen. CH or CNFb; D is a group S(O)x wherein x is 0, 1 or 2, a C 1.4 alkylene chain, or a C2.4 alkenylene or alkynylene chain; d is 0 or 1 ; Ar is a monocyclic or bicyclic ring system which may contain one or two heteroatoms and which contains at least one aromatic ring; R- represents hydrogen or one to three substituents on the ring system Ar which may be the same or different and are chosen from halo, NR-^R^ wherein R? and R^ are independently selected from hydrogen or S(O)x> R wherein x' is 0, 1 or 2 and R^ is Cj_4 alkyl; nitro, cyano. a C1.4 carboxcylic acid group or an ester thereof, C\__ alkyl optionally substituted by one to three halo atoms; phenyl or a group -(A)mR^ wherein A represents oxygen, S(O)n wherein n is 0, 1 or 2, or NR^ wherein R^ is hydrogen or C\__ alkyl optionally substituted by halo and m is 0 or 1, and R$ is hydrogen, or C 1.4 alkyl or phenyl each optionally substituted by one to three halo atoms; R^ is hydrogen, C\__ alkyl, hydroxy, halo, trifluoromethyl or a group NRIORI * wherein R^ and R-- 1 are the same or different and each is hydrogen or Cj_4 alkyl, or NRI ORI I forms a 5- or 6- membered heterocyclic group optionally substituted by a C\__ alkyl group or R^ represents a C _2 alkylene group linking the heterocyclic ring to Ar.
Preferred heterocyclic groups include morpholino, piperidino and methylpiperazino.
Formula (I A)
or a salt thereof, wherein R** ,R-***,X,Y,R4 are as hereinbefore defined, Ar' is a monocyclic or bicyclic ring system containing at least one aromatic ring, and R**-' represents hydrogen or one to three substituents which may be the same or different and are chosen from halo, amino, nitro, cyano. a C1.4 carboxylic acid group or an ester thereof, a group -(A)mR° wherein A and m are as hereinbefore defined and R***' is C 1.4 alkyl optionally substituted by halo;
Preferred compounds of the formula (I A) include those of the formula (III)
SUBSTITUTE SHEET H or a salt thereof
wherein D. d, Ar, R***, R**, R2> X and R^ are as hereinbefore defined.
For formulae (IA), (II) and (III):
Suitably d is 0;
Suitably Ar is phenyl, naphthyl, tetrahydronaphthyl, or benzothienyl.
Preferably Ar is phenyl.
Suitably R**-1 is halo, most suitably chloro or bromo, C1.4 alkyl or C 1.4 alkoxy, preferably methoxy. Preferably there are one or two substituents which are at the 3-, 4- or 5- positions of the phenyl ring (when Ar is phenyl) or at a position not α- to the linkage of the group Ar to the nitrogen containing aromatic ring when Ar is not phenyl. Preferably, when Ar is phenyl the. or one of the. subsituents is at the 4-position of the phenyl ring.
Suitably R-* and R~ are hydrogen, methyl, ethyl or NR--R**-- is a methyl-piperazino group. Preferably R*1 and R- are hydrogen.
R4 is most suitably hydrogen or NEb and preferably R^ is hydrogen.
For formulae (IA) and (II) Y is preferably CNH2
Suitable compounds of the formula (IA) include
2,4-diamino-6-(4-methoxyphenyl)pyrimidine
2.4-diamino-6-(3 ,4-dimethoxypheny l)pyrimidine
2.4-diamino-5-(2-(4-methylphenyl)ethyl)pyrimidine
2.4-diamino-5-(4-methylphenylethynyl)pyrimidine
2.4-diamino-5-phenylethynylpyrimidine
2.6-diamino-3-(2.4.5-trichlorophenyl)pyridine
SUBSTITUTE SHEET 2.6-diamino-3-(4-methoxyphenyl)pyridine
2.6-diamino-3-(2-naphthyl)pyridine
2.6-bis(acetamido)-3-(3,4-dimethoxyphenyl)pyridine
2,6-diamino-3-(3,4-dimethoxyphenyl)pyridine l-amino-2, 4-diaza-5, 6-dihydro-9-methoxy-3-(4-methyl-l-piperazinyl)phenanthrene
4-amino-9. 10-dihydro-7-methoxy-2-(4-methyl-l-piperazinyl)benzo [f] quinazaline
2-amino-5-((-naphthyl)pyrimidine
2-amino-5-(4-methoxyphenyl)pyrimidine
2-(4-methylpiperazinyl)-5-(2-naphthyl)pyrimidine
5-(3 ,4-dimethoxy)-2-(4-methyl- 1 -piperazinyl)pyrimidine
5-(1.3-benzo[d]dioxol-5-yl)-2-(4-methylpiperazin-l-yl)pyrimidine
5-( 1 ,4-benzodioxan-6-yl)-2-(4-methylpiperazin- 1 -yl)pyrimidine
5 -(3 ,4-dichlorophenyl)-2-(4-methylpiperazinyl)pyrimidine
2,4-diamino-5- 3 -thieny l)pyrimidine 2,4-diamino-5- 3,5 -dimethoxypheny l)pyrimidine 2,4-diamino-5- 2,5-dimethoxyphenyl)pyrimidine
2,4-diamino-5-biphenylpyrimidine
2,4-diamino-5 3,5 -bis(trifluoromethy l)phenyl)pyrimidine
2.4-diamino-5 3 , 5 -dichloropheny l)pyrimidine
2,4-diamino-5 2,5-dibromo-4-chlorophenyl)pyrimidine
2.4-diamino-5-i 4-chloro-3-methanesulphonamidophenyl)pyrimidine
2.4-diamino-5 4-methoxy-3-methylphenyl)pyrimidine
2.4-diamino-5- 4-trifluoromethylphenyl)pyrimidine
2.4-diamino-5- 4-trifluoromethoxyphenyl)pyrimidine
2.4-diamino-5 3-amino-4-chlorophenyl)pyrimidine
2,4-diamino-5- 3 -aminophenyl)pyrimidine
2,4-diamino-5- 4-chloro-3-nitrophenyl)pyrimidine
2,4-diamino-5- 3-chloro-4-hydroxyphenyl)pyrimidine
2,4-diamino-5- 3 -fiuorophenyl)pyrimidine
2.4-diamino-5- 3-trifluoromethoxyphenyl)pyrimidine
2.4-diamino-5- 3-bromo-4-methoxyphenyl)pyrimidine
2.4-diamino-5- 3-fluoro-4-methoxyphenyl)pyrimidine
2.4-diamino-5-' 3-chloro-4-methoxyphenyl)pyrimidine
2.4-diamino-5 3-chloro-4-fluorophenyl)pyrimidine
2.4-diamino-5 4-chlorophenyl)pyrimidine 1.3-diamino-5. 6-dihydro-7-methoxy-2. 4-phenanthroline 1.3-diamino-5. 6-dihydro-8-methoxy-2. 4-phenanthroline
SUBSTITUTE SHEET 1.3-diamino-5. 6-dihydro-9-methoxy-2, 4-phenanthroline
3-(2. 4-diamino-5-pyrimidinyl)phenol
2.4-diamino-5-(3-methoxyphenyl)pyrimidine
2J-diamino-6-(4-nitrophenyl)pyrimidine
2 J-diamino-5 -(3 ,4-dimethoxyphenyl)pyrimidine
2.4-diamino-5-(3,4,5-trimethoxyphenyl)pyrimidine
2,4-diamino-5-(4-fluorophenyl)pyrimidine
2,4-diamino-5-(4-methoxyphenylthio)pyrimidine
2,4-diamino-5-phenethylpyrimidine
2.4-diamino-5-(4-chlorophenylthio)pyrimidine
2,4-diamino-5-(4-chlorophenylsulphonyl)-6-methylpyrimidine or a salt thereof.
Preferred compounds of the formula (IA) include:
2, 4-diamino-5-(3, 4-dichlorophenyl)pyrimidine 2. 4-diamino-5-(4-methoxyphenyl)pyrimidine 2, 4-diamino-5-(4-methylphenyl)pyrimidine 2. 4-diamino-5-(4-chlorophenyl)pyrimidine 2. 4-diamino-5-(3-chlorophenyl)pyrimidine 2, 4-diamino-5-(2, 4-dichlorophenyl)pyrimidine 2.4-diamino-5-(3-trifluoromethylphenyl)pyrimidine 2. -4-diamino- 5 -(3 -bromopheny l)pyrimidine 2.4-diamino-5-(3-methylphenyl)pyrimidine 2.4-diamino-5 -(3 ,4-methylenedioxyphenyl)pyrimidine 2.4-diamino-5-(3,4-ethylenendioxyphenyl)pyrimidine or a salt thereof
2)
an ed by halo or alkoxy and preferably R^~ is a substituent at 3. 4 or 5 position. (+-)-2-Amino-6-[[(4-
SUBSTITUTE SHEET chlorophenethyl)oxy]methyl]-5, 6, 7, 8-tetrahydro-4(3H)-pteridinone is an example of a compound of the formula (IB). These compounds bind less strongly than those of formula (IA).
wherein R^~, R^, Rl5 a^j R16 ^Q each separately selected from hydrogen, halo, haloalkyl, formyl, carboxy, sulpho, cyano, nitro, COR --8 and +NR18R19 20? wherein R1^, R 9 and R-® are each separately alkyl, aralkyl or aryl groups and R-*^ is selected form hydrogen, halo, haloalkyl, formyl, carboxy, sulpho, cyano, nitro, hydroxy, alkoxy, alkyl, COR18, NHCOR18 and +NR18R19R20 groupSj wherein R185 R19 and R2° are each separately alkyl aralkyl or aryl groups.
The standard system of numbering is used herein for the indazole ring system as shown below
As regards the groups R -*•*•■, R**^, Rl and Rl6. the halo and haloalkyl groups may for example be a fluoro, bromo, iodo or particularly a chloro group or a Cι_i2> particularly C\_β, straight or branched chain alkyl group, for example an ethyl or especially a methyl group, substituted by one or more, for example three, such halo groups. Aralkyl and aryl groups R *• **, Rl9 and R20, may conveniently be or contain various forms of aromatic hydrocarbyl group but 1- or 2-naphthyl and particularly phenyl groups are of most interest. Alkyl and aralkyl group R** **-*, Rl9 and R****0 may conveniently be or contain alkyl group such as are described above in relation to the haloalkyl groups R^~, R^, R-*-\ Rl6. Particular examples of groups COR^ and +NR** 8R19R20 ^g hus propionyl and especially acetyl, and triethylamino and especially trimethylamino.
SUBSTITUTE SHEET As regards the group R^, similar comments apply to halo, haloalkyl. COR**8 and +NR1 8R1 9R20 groups as for R13, R14, R15 and R16 whilst the alkyl groups R1 7 may conveniently be selected similarly to the alkyl portion of the halo alkyl groups R^ . R--4, R***-*", R-- 6 and R^ and the groups R^ in NHCOR** 8 may conveniently be selected as for the groups R1 8 in COR18 and +NR1 8R1 9R20; the group NHCOR1 8 being for example propionamido or acetamido.
Although each of the groups R-*3, R-*4, R**-5 and R-*^ may be hydrogen it is preferred that at least one is other than hydrogen, particularly the group R-*4 or R*-5 or especially R-*3, although preferably two or three of R 3, R* , R***** and Rl°" are hydrogen. As regards the groups which are other than hydrogen, the groups which are preferred are those which effect a significant degree of electron withdrawal from the benzene ring. Accordingly a nitro group is of particular interest. Other groups of interest, possibly together with another type of group such as nitro, are haloalkyl and especially halo groups.
Although groups +NR1 R19 205 for example trialkylamino groups such as trimethylamino, also possess this ability their charged nature is a disadvantage in terms of entry into the brain across the blood/brain barrier.
It will be appreciated that where more than one of R^ , R-*4, R! *** and R1 °" is other than hydrogen the two or more substituents may differ from each other. Conveniently however at least one. for example R^3, is one of the groups just indicated as being of interest.
Although RΪ7 may be other than hydrogen, for example a halo group such as chloro. it is preferably hydrogen.
Moreover, when one or more of R*3, R^4, R^ or R--6 is a group +NR1 R-* R 0 the compounds will be a quaternary ammonium salt which contains one or more physiologically acceptable anions. Such anions may for example correspond to those present in the acid addition salts hereinafter described but halo groups such as chloro and bromo are preferred.
Furthermore, when an acid substituent R-*-\ R^4, R-**--. Rl6 0r R**7 such as carboxy or sulpho is present then the physiologically acceptable salt may be one formed with a suitable base, examples of which are the alkali metal hydroxides, for example sodium hydroxide, quaternary ammonium hydroxides and amines such as tris (tris representing 2-amino-2- hydroxymethyl propane 1.3-diol).
SUBSTITUTE SHEET When a carboxy or sulpho substituent is present or when a hydroxy group is present the indazoles (IC) can be used in the form of physiologically acceptable ester. Such esters may be formed respectively with a suitable phenol or alcohol or with a suitable organic acid or even inorganic acid. Of paπicular interest are esters formed with a C 1.12, particularly C\_ alkanol. for example ethyl and especially methyl esters.
Examples of specific indazoles (IC) of use in the present invention are indazole and its 4-, 5-, 6- and 7-nitro derivatives together with their halogeno, for example chloro or bromo, analogues. Of these indazole and the last three mentioned nitro derivatives, especially 7- nitroindazole, are of particular interest.
The compounds of formula (IA) (IB) and (IC) may include a number of asymmetric centres in the molecule depending on the precise meaning of the various groups and formula (IA) (IB) and (IC) are intended to include all possible isomers.
The activity of a compound as a tetrahydrobiopterin-site inhibitor of neuronal NO synthase can be determined by an assay in which L-[-* C]-arginine is convened to [U^4C]-citrulline by brain cytosol NO synthase (as described by Salter et al., FEBS Lett. 221, 1991 , 145-149) following a preincubation with the compound in the absence or presence of a saturating concentration (typically lOμM) of tetrahydrobiopterin). Such inhibitors also show activity in an intact cell system in which conversion of [^4C]-L-arginine to [^4C]-citrulline is measured in brain slices stimulated with veratrine. In these experiments, single coronal slices of adult rat forebrain are preincubated in Krebs-Henseleit buffer before transfer to fresh buffer containing L-[U-^4C]-arginine. lOμg/ml veratrine and various concentrations of test compound (routinely 1- lOOμM). The mixture of test compound and coronal slices is then incubated and the level of [U--*4C]-citrulline formed, then determined (essentially as described-previously, Salter et al 1991). Selectively for the neuronal NO synthase can be determined by comparison with enzyme assays for other forms of NO synthase or by comparisons with intact cell preparation NO synthesis such as in rat aortic rings in which the basal tone of the tissue is used as an indication of the activity of the constitutive NO synthase.
Alternatively, the activity of the compounds can be determined by the method of Dwyer et al, Biochem. Biophys. Res. Commun. 1991. 176. 1 136-1 141.
SUBSTITUTE SHEET Conditions in which there is an advantage in selectively inhibiting neuronal NO production include cerebral ischemia, CNS trauma, epilepsy, AIDS dementia, chronic neurodegenerative disease (eg Parkinson's disease), schizophrenia and chronic pain, and conditions in which non-adreneric non-cholinergic nerve may be implicated such as priapism. obesity and hyperphagia. They are also suitable for use as analgesics and in the treatment of acute neurodegenerative diseases, for example in the treatment of convulsions or particularly for prophylactic use in the prevention of an ischemic incident and possibly also in memory enhancement.
As used herein, reference to "treatment" of a patient is intended to include prophylaxis.
The present invention includes neuronal NO inhibitors in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non- pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic. hydroiodic, sulphuric, nitric, citric, tartaric, phosphoric, phosphonic, lactic, pyruvic, acetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonic and isethionic acids. Salts of neuronal NO inhibitors can be made by reacting the appropriate compound in the form of the free base with the appropriate acid. Esters are pharmaceutically acceptable esters, for example C1.4 alkyl esters.
A further aspect of the present invention provides a compound of formula (IA), (IB) or (IC) or a salt thereof for use in medicine, with the proviso that R 2 is not hydrogen, and that R-*4 and R--5 are not independently selected from hydrogen, nitro or carboxy when R-*3, R} ~ and R^are each hydrogen.
Many compounds of formula (IA), (IB) or (IC) or salts thereof are novel, and accordingly the invention also provides:
(i) novel compounds of formula (IA) and salts thereof. Such compounds include:
2.4-diamino-5-(3-trifluoromethylphenyl)pyrimidine 2.-4-diamino-5-(3-bromophenyl)pyrimidine 2.4-diamino-5-(3-methylphenyl)pyrimidine 2.4-diamino-5-(3.4-methylenedioxyphenyl)pyrimidine
SUBSTITUTE SHEET 2.4-diamino-5-(3,4-ethylenendioxyphenyl)pyrimidine
2.4-diamino-6-(4-methoxyphenyl)pyrimidine
2,4-diamino-6-(3.4-dimethoxyphenyl)pyrimidine
2.4-diamino-5-(2-(4-methylphenyl)ethyl)pyrimidine
2.4-diamino-5-(4-methylphenylethynyl)pyrimidine
2,4-diamino-5-phenylethynylpyrimidine
2,6-diamino-3-(2,4.5-trichlorophenyl)pyridine
2,6-diamino-3-(4-methoxyphenyl)pyridine
2.6-diamino-3-(2-naphthyl)pyridine
2,6-bis(acetamido)-3-(3,4-dimethoxyphenyl)pyridine
2.6-diamino-3-(3,4-dimethoxyphenyl)pyridine l-amino-2. 4-diaza-5. 6-dihydro-9-methoxy-3-(4-methyl-l-piperazinyl)phenanthrene
4-amino-9. 10-dihydro-7-methoxy-2-(4-methyl-l-piperazinyl)benzo[f]quinazoline
2-amino-5-((-naphthyl)pyrimidine
2-amino-5-(4-methoxyphenyl)pyrimidine
2-(4-methylpiperazinyl)-5-(2-naphthyl)pyrimidine
5-(3 ,4-dimethoxy)-2-(4-methyl- 1 -piperazinyl)pyrimidine
5-( 1 ,3-benzo[d]dioxol-5-yl)-2-(4-methylpiperazin- 1 -yl)pyrimidine
5-(l ,4-benzodioxan-6-yl)-2-(4-methylpiperazin-l -yl)pyrimidine
5 -(3 ,4-dichlorophenyl)-2-(4-methylpiperazinyl)pyrimidine
2,4-diamino-5* 3 -thieny l)pyrimidine 2.4-diamino-5* 3.5 -dimethoxypheny l)pyrimidine 2.4-diamino-5* 2,5-dimethoxyphenyl)pyrimidine
2.4-diamino-5-biphenylpyrimidine
2.4-diamino-5 3 ,5 -bis(trifluoromethy l)phenyl)pyrimidine
2.4-diamino-5 3 , 5 -dichl oropheny l)pyrimidine
2.4-diamino-5 2,5-dibromo-4-chlorophenyl)pyrimidine
2.4-diammo-5 4-chloro-3-methanesulphonamidophenyl)pyrimidine
2,4-diamino-5 4-methoxy-3-methylphenyl)pyrimidine
2.4-diamino-5 4-trifluoromethylphenyl)pyrimidine
2,4-diamino-5 4-trifluoromethoxyphenyl)pyrimidine
2.4-diamino-5 3-amino-4-chlorophenyl)pyrimidine
2.4-diamino-5 3-aminophenyl)pyrimidine
2,4-diamino-5 4-chloro-3-nitrophenyl)pyrimidine
2.4-diamino-5 3-chloro-4-hydroxyphenyl)pyrimidine
2.4-diamino-5- 3-fluorophenyl)pyrimidine
2.4-diamino-5- 3-trifluoromethoxyphenyl)pyrimidine
SUBSTITUTE SHEET 2.4-diamino-5-(3-bromo-4-methoxyphenyl)pyrimidine
2.4-diamino-5-(3-fluoro-4-methoxyphenyl)pyrimidine
2,4-diamino-5-(3-chloro-4-methoxyphenyl)pyrimidine
2.4-diamino-5-(3-chloro-4-fluorophenyl)pyrimidine
2.4-diamino-5-(4-chlorophenyl)pyrimidine
(ii) compounds of formula (IB) and salts thereof with the proviso that R--2 is not hydrogen; and
(iii) novel compounds of formula (IC) and salts thereof.
Whilst it may be possible for the neuronal NO synthase inhibitors of the present invention to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. According to a further aspect, the present invention provides a pharmaceutical formulation comprising a compound which binds at the tetrahydrobiopterin site of NO Synthase in combination with a pharmaceutically acceptable carrier therefor and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (IA), (IB) or (IC) or a pharmaceutically acceptable salt or solvate thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration my be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient: as a powder or granules: as a solution or a suspension in an aqueous liquid or a non-aqueous liquid: or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
SUBSTITUTE SHEET A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water- for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration mav include flavourins aeents.
SUBSTITUTE SHEET The neuronal NO synthase inhibitors of the invention may be administered orally or via injection at a dose of from 0J to 500mg/kg per day. The dose range for adult humans is generally from 5mg to 35g/day and preferably 5mg to 2g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5mg to 500mg, usually around lOmg to 200mg.
The neuronal NO synthase inhibitors of the invention are preferably administered orally or by injection (intramuscular, intravenous or subcutaneous). The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration may vary depending on the condition and its severity.
The present invention also provides a process for the preparation of the novel compounds of formula (IA), (IB) and (IC) as hereinbefore defined
Compounds of the present invention are commercially available or may be made by analogous methods to those known in the art. More specifically:
(a) Compounds of formula (I A) may be prepared
(i) when X is nitrogen, by the cyclisation of a compound of the formula (IV)
wherein R21 is cyano or COR23 wherein R 3 is hydroxy, C1.4 alkoxy or hydrogen and R22 is oxo or a group C^ H wherein L is a leaving group; with amino guanidine or guanidine respectively. Suitable leaving groups include alkoxy and substituted secondary amino groups, eg. aniline and substituted aniline groups and heterocyclic amines such as morpholine.
The reaction conveniently takes place in a polar solvent, for example an alkanol. e.g. a C ] _4 alkanol such as ethanol. or a dipolar aprotic solvent such as
SUBSTITUTE SHEET o o dimethvlsuiphoxide at a non-extreme temperature, e.ε. 20 to 150 C and o o conveniently 25 to 90 C, with the guanidine or aminoguanidine present in the form of a salt. The free guanidine or aminoguanidine can then conveniently be liberated in-situ by the presence of base, for example an alkoxide such as sodium methoxide. When the guanidine or aminoguanidine is in the form of its carbonate/bicarbonate, base is not required.
These reactions are analagous to those described in UK patent 1261455, UK patent 002121 and European patent application EP 0372934 for the preparation of benzyl pyrimidines. trizines and phenyl pyrimidines respectively
(ii) when R and R2 are hydrogen the removal of one or more protecting groups from NR*R and optionally from R4, when it is desired that R4 is NK . Suitable protecting groups are derived from carboxylic acids, for example acetic or benzoic acids.
(iii) by the conversion of one compound of the formula (I A) to a further compound of the formula (IA), for example when Rl and/or R are C 1.4 alkyl the alkylation of the corresponding compound wherein Rl and/or R are hydrogen; or when R^ and R are hydrogen, the amination, or chlorination and subsequent animation, of a compound of the formula (V):
wherein Q is chloro or bromo, preferably chloro, or hydroxy respectively and R4' is hydrogen, methyl, hydroxy, trifiuoromethyl or halo. Suitable chlorinating agents include phosphorous oxychloride which can also be used as solvent. The amination is conveniently carried out by reaction with ammonia in a suitable solvent such as a
C]_4 alkanol. e.ε. ethanol. The reaction is suitably carried out at an elevated o temperature, for example 50-200 C. in a sealed system, and preferably under pressure.
(iv) when X is CH and Y is a group CH or CNH2 the reaction of a compound of the formula (VI):
SUBSTITUTE SHEET or a suitably protected derivative thereof, wherein R24 is hydrogen or NH2 with benzene boronic acid or benzene boronic acid substituted so as to give the desired substituent R^ •■ in the compound of the formula (IA) so formed, followed by the removal of any protecting groups.
This reaction is conveniently carried out in the presence of a catalyst, for example a palladium catalyst. We have found that tetrakistriphenylphosphine palladium is a suitable catalvst for this reaction. The reaction is convenientlv carried out at a non- o o o o extreme temperature, for example 20 to 100 C and preferably 50 to 90 C in a solvent, for example a mixture of an aromatic hydrocarbon such as benzene and an alkanol such as ethanol under ξin inert atmosphere. Acyl groups, for example acetyl groups, are suitable protecting groups when R-*^ and/or R b are hydrogen.
(b) Compounds of the formula (IB) may be prepared by the reduction of the corresponding 8-oxide. This is conveniently accomplished by hydrogenation in the presence of a suitable catalyst. The catalyst will normally be a transition metal catalyst, for example containing palladium or platinum, and will be chosen so that it reduces the 8-N-oxide function without affecting any of the other groups in the molecule, unless it is desired to also reduce these. We have found that palladium
(as a 5% of a mixture with barium sulphate) is a suitable selective catalyst. The reaction is conveniently carried out in a solvent, for example a glacial acetic acid/trifluoroacetic acid mixture, at a non-extreme temperature, for example between o o
0 - and 80 C and suitably at room temperature.
(c) Compounds of formula (IC) can be prepared using various routes to indazoles described in the literature, for example the process of U.S. Patent 3, 988, 347 which involves reaction of o-methylacetanilide containing the appropriate substituents R13^ R14_ R15 ancj R16 or substitutents convertible thereto. Indazoles (IC) having a substituent at the 3-position. i.e. containing a group R^ other than hydrogen may be prepared by other procedures described in the art of indazole chemistry or by modification of those procedures.
SUBSTITUTE SHEET The compounds may be prepared directly in salt form or converted thereto by reaction of the indazole with the appropriate acid or base. Esters may similarly be prepared directly or through acid or base. Esters may similarly be prepared directly or through reaction of the corresponding indazole containing a carboxy or sulpho group with the appropriate alcohol or of the corresponding indazole containing a hydroxy group with the appropriate acid.
The present invention also provides a novel process for the preparation of a compound of formula (IA) as hereinbefore defined, which comprises the reaction of a compound of formula (VII).
or a suitably protected derivative thereof with a compound of formula R3-Ar-(D)cj-B(OH)2 wherein R-*, R2, R3, R4, Ar, D, d, X and Y are as hereinbefore defined, followed by deprotection if necessary.
Preferably d is 0 and/or Ar is phenyl.
The reaction is conveniently carried out in a polar solvent, for example toluene, in the presence of aqueous sodium carbonate and tetrakistriphenylphosphine palladium, under an inert atmosphere, for example nitrogen. The reaction is preferably carried out at a non- extreme temperature of 20°C to 150°C, suitably 80°C to 120°C.
Compounds of formula (VII) may be prepared from a compound of formula (VIII)
or a suitably protected derivative thereof wherein R*, R , R4, X and Y are as hereinbefore defined, by reaction with iodine monochloride. The reaction is carried out in a suitable solvent, such as glacial acetic acid, at non-extreme temperature for example room temperature.
SUBSTITUTE SHEET The present invention will now be described by way of example only, and is not intended to be limiting thereof.
Example 1
Preparation of 5-fBenzo-[B]-thien-3-vO-2.4-diaminopyrimidine
(a) 2- Benzo-[B]-thien-3-ylV3-methoxyacrylonitrile
To a solution of sodium ethoxide (from l.lgms of Na) in ethanol (60ml) at room temperature was added benzo-[B]-thien-3-yl acetonitrile (7.79gms, Maybridge Chemicals Ltd) in a single portion. Stirring was continued for 15 minutes, ethylformate (6.66gms) added, and the mixture left to stir overnight at room temperature. The suspension was then refluxed for 3 hours during which time the solid completely dissolved. After cooling, the solvent was removed in vacuo and the residue triturated with diethyl ether. The solid was filtered off and dried in vacuo to leave the crude product as a tan coloured solid (6.93gms).
The above product was divided into three equal portions. These were placed in separate Young tubes, methvl iodide (l.δgms) and DMF/18mls) added to each, and o the tubes sealed. After stirring at 50 C for 4 hours the contents were cooled, combined, and the solvent removed in vacuo. The residue was then partitioned between ethyl acetate and water, and the organic phase again washed with water before drvinε over MgSO . After treating with activated charcoal, the solvent was
4 evaporated to leave the desired product as a pale yellow waxy solid. (4.8 gms. 50% yield)
(b) 5-fBenzo-[BJ-thien-3-ylV2.4-diaminopyrirnidine
To a solution of sodium ethoxide (from 1.03gms of Na) in ethanol (40ml) at room temperature was added guanidine HC1 (4.26gms). After stirring for a further 5 minutes, the above intermediate was added in ethanol (40ml) and the resulting suspension refluxed for 5 hours. After cooling, the solvent was removed in vacuo and the residue partitioned between chloroform and water. After washing the organic phase with water and drying over MgSO4, the solvent was removed in vacuo. The crude product was then purified by column chromatography (Siθ2)
SUBSTITUTE SHEET elutinε with CHCI3 to 4% MeOH-CHCl3. Recrvstallization from ethanol εave the o product as a white crystalline solid. (2.7εms. 50% vield, mp 193-4 C)
The following compounds were made by an analogous method:
-methoxy-3-methylphenyl)pyrimidine; mpt = 229-230°C -trifluoromethylphenyl)pyrimidine: mpt = 218-219°C -trifluoromethoxyphenyl)pyrimidine; mpt •= 174-175°C -fluorophenyl)pyrimidine; mpt = 215-217°C -trifluoromethoxyphenyl)pyrimidine; mpt = 197.7-199.6°C -bromo-4-methoxyphenyl)pyrimidine; mpt = 269.3-271.8°C -fluoro-4-methoxyphenyl)pyrimidine; mpt = 243-245°C -chloro-4-methoxyphenyl)pyrimidine; mpt = 337-339°C -chloro-4-fluorophenyl)pyrimidine; mpt = 233-235°C -methylphenyl)pyrimidine; mpt = 167-169°C -bromophenyl)pyrimdine; mpt = 215.7-218.5°C -trifluoromethylphenyl)pyrimidine; mpt = 260-261°C -bromo-4-chloro)pyrimidine; mpt = 221-222°C -chloro-4-methyl)pyrimidine; mpt = 281-282°C
Example 2
Preparation of 2.6-Diamino-3J3.5-dichlorophenyDpyridine
(a) 2.6-Diaceτamido-3-G.5-dichlorophenyl)pyridine
To a mixture of 3-bromo-2,6-diacetamidopyridine (2.00g, Alfred Bader Library of Rare Chemicals; Div. of Aldrich Chemical Company, INC.) in benzene (15ml), 2M aqueous sodium carbonate (7.36ml) and tetrakistriphenylphosphine palladium (0.25g), a solution of 3.5-dichlorobenzene boronic acid (1.52g) in absolute ethanol (3ml) was slowly added. The yellow biphasic reaction mixture was refluxed under nitrogen for 6 hours. The reaction mixture was cooled to room temperature and evaporated under reduced pressure. The residue was partitioned between water and chloroform. The chloroform layer was washed once with saturated sodium bicarbonate, twice with water and dried over anhydrous magnesium sulphate. The solvent was removed under vacuo and the crude product was purified by column chromatography (Siθ2) eluting with chloroform to 2% methanol-chloroform. The
SUBSTITUTE SHEET product was triturated with ether, filtered and dried under vacuo at 60°C to give a white solid. (0.738g, mp 200-204°C.)
(b) 2.6-Diamino-3-(3.5-dichlorophenyl)pyridine
2,6-Diacetamido-3-(3,5-dichlorophenyl)pyridine was suspended in dilute hydrochloric acid (0.40ml, 12M HCl/lml H2O) and refluxed at 120°C for 1.50 hours. The reaction mixture was cooled in an ice-bath and basified with 0.880 ammonia. The white solid which precipitated was filtered, washed with water and dried under vacuo at room temperature. The crude product was purified by column chromatography [SiO?] elutinε with ether. The product was triturated with o petroleum ether, filtered and dried under vacuo at 70 C to give a cream solid.
(0J07g, mp l l4-116°C.)
Example 3
Preparation of 2. 4-diamino-5-(4-phenoxyphenyDpyrimidine
(a) 2.4-diamino-5-iodopyrimidine
A soloution of iodine monochloride (16.24g, OJmol) in glacial acetic acid (5ml.) was added dropwise with stirring during 30 minutes to a mixture of 2,4- diaminopyrimidine (l lg. OJmol) and glacial acetic acid (150ml). The mixture became homogeneous towards the end of the addition and then the product hydrochloride began to separate. The thick slurry was vigorously stirred for 4 hours then filtered. The filter cake was sucked as dry as possible then dissolved in hot water (400ml). Solid sodium sulphite was added in small portions until the iodine colour was completely discharged. The solution was filtered and the filtrate was basified with lON.NaOH. Cooling in the refrigerator overnight gave the product as a cream cystalline solid (18.9g. 80% yield, m.p. 229-230).
(b) 2.4-diamino-5-f4-phenoxyphenvπpyrimidine
A mixture of 2,4-diamino-5-iodopyrimidine (lJ 8g. 5mmol), 4-phenoxy- benzeneboronic acid (1.28g. 6mmol), toluene (40 ml), 2M aqueous sodium carbonate (10ml. 20mmol) and tetrakistriphenylphosphine palladium (400 mg. 0.35 mmol) was stirred and heated at 1 10°C under nitrogen for 6 hours. The reaction
SUBSTITUTE SHEET mixture was evaporated to dryness in vacuo and the residue was washed with warm water and taken up in dichloromethane. The organic extract was dried (MgSO4) and evaporated to drynes in vacuo. The residue was purified by flash column chromatography (Siθ2). Elution with CH2CI2 to 5% EtOH-CH2Cb gave a solid which after recrystallisation form EtOH afforded the product as a cream crystalline solid (860mg 62% yield, m.p. 149).
The following compounds were prepared by an analgous method:
2,4-diamino-6-(4-methoxyphenyl)pyrimidine; mpt. 220-222°C 2,4-diamino-6-[3,4-dimethoxyphenyl]pyrimidine; mpt 202-204°C 2.4-diamino-5-[2-(4-methylphenyl)ethyl]pyrimidine; mpt 187°C 2.4-diamino-5-(4-methylphenylethynyl)pyrimidine: mpt 197-199°C 2.4-diamino-5-phenylethynylpyrimidine; mpt 190°C 2.6-diamino-3-(2,4,5-trichlorophenyl)pyridine; mpt 173-175° C 2,6-diamino-3-(4-methoxyphenyl)pyridine; mpt 131° 2,6-diamino-3-(2-naphthyl)pyridine; mpt 193-194°C 2,6-Bis(acetamido)-3-(3,4-dimethoxyphenyl)pyridine; mpt 231-233°C 2,6-diamino-3-(3,4-dimethoxyphenyl)pyridine; mpt 190° C 2,4-diamino-5-[3,4-ethylenedioxyphenyl]pyrimidine; mpt 222-224°C 2,4-diamino-5-[3,4-methylenedioxyphenyl]pyrimidine: mpt 225-227°C 2-amino-5-(l-naphthyl)pyrimidine: mpt 155°C 2-amino-5-(4-methoxyphenyl)pyrimidine; mpt 183-184°C 2.4-diamino-5-(3-thienyl)pyrimidine; mpt 171-172°C 2,4-diamino-5-(3,5-dimethoxyphenyl)pyrimidine; 2,4-diamino-5-(2.5-dimethoxyphenyl)pyrimidine; mpt 157°C 2,4-diamino-5-biphenylpyrimidine; mpt 204-206°C 2.4-diamino-5-[3,5-bis(trifluoromethyl)phenyl]pyrimidine; mpt 201-203°C 2,4-diamino-5-(3.5-dichlorophenyl)pyrimidine; mpt 289-292°C
Example 4
The following compounds were made by conversion of a compound of formula (IA) according to the reaction scheme shown in Fig. 1.
(1 ) 2.4-diamino-5-(3-chloro-4-hydroxyphenyl)pyrimidine; mpt = 165-167°C
(2) 2,4-diamino-5-(4-chloro-3-nitrophenyl)pyrimidine; mpt = 245-246°C
SUBSTITUTE SHEET T)
(3) 2,4-diamino-5-(3-aminophenyl)pyrimidine: mpt = 156-157°C
(4) 2.4-diamino-5-(3-amino-4-chlorophenyl)pyrimidine; mpt = 189-190°C
(5) 2,4-diamino-5-(2,5-dibromo-4-chlorophenyl)pyrimidine; mpt = 245-248°C
(6) 2.4-diamino-5-(4-chloro-3-methanesulphonamidophenyl)pyrimidine; mpt = 234-235°C
(7) 2,4-diamino-5-(4-chloro-3-cyanophenyl)pyrimidine; mpt > 300°C
Example 5
Preparation of (+-)-2-Amino-6-[[(4-chlorophenethyl oxy]methyl]-5.6.7.8-tetrahy-dro- 4f3HVpteridinone
a) 2- Amino-6- [[(4-chlorophenethyl)oxy]methy 1] -4(3 H)- pteridinone 8-oxide
The title compound was prepared from 3-amino-6-chloromethyl- 2-pyrazinecarbonitrile 4-oxide and 4-chlorophenethanol by the method of Bigham et al, J.Med.Chem. 1987, 3β, 40-45.
b) f+-)-2-Amino-6-[[f4-chlorophenethvDoxy]methyl]-5.6.7.8- tetrahy dro-4C3 H Vpteri dinone
A mixture of 2-amino-6-[[(4-chlorophenethyl)oxy]methyl]-4(3H)- pteridinone 8-oxide monohydrate (0.600g), 5%Pd/BaSO (0.200-0.300g), glacial acetic acid (40ml), and trifluoroacetic acid (20ml) was hydrogenated a total of three times for a total of lh 23min. The total uptake of hydrogen was 111 ml. 6N HCl
(10ml) was added. After 3h, the mixture was filtered, and the yellow filtrate was evaporated to dryness. The crude product was dissolved almost completely in hot
6N HCl (100ml), and the solution was treated with charcoal, filtered, and cooled.
The resulting mixture was concentrated under vacuum to a solid that was dissolved in hot 6N HCl (70ml). The solution was allowed to cool, and the crystallized white o solid was filtered, washed with 6N HCl (2x10 ml), and dried under vacuum at 50 C: yield 0.474g = mp 232-237 C (dec); IR(KBr) 1663 (CO) overlapping less intense
1700 cm"1 : NMR(Me2SO-δ6) d 2.81(t.2H,CU2 Cl); 3J-3.2(mJH,C-6H); 3.3-3.5(br d.2H.c-7 H2); 3.5-3.8(m. 4H, £H2θ£H2); 5.6(br); 6.78(br s, 2H, NH ); 7.24-7.35
(AA'XX'. 4H, ArH); 7.42 (br s. 1H. NH); 1 10.0 (very br); 10.75 (br"s, 1H. NH):
UV(0JN HCl) λ max 265.5 nm (e 13800); Anal.C ι5H1 8ClN5θ2.2HCl.H2θ
(C.H.N.Cl).
SUBSTITUTE SHEET Example 6
Biological Activity of Compounds of the Present Invention
The activity of a compound as a tetrahydrobiopterin-site inhibitor of neuronal NO synthase was determined by an assay in which L-[U--4C]-arginine is convened to [U*-4C]-citrulline by brain cytosol NO synthase (as described by Salter M. Knowles. R.G. and Moncada, S. (1991) FEBS Lett. 291, 145-149. following a 5 min preincubation with the compound in the absence or presence of a saturating concentration (typically lOμM) of tetrahydrobiopterin). Compounds were initially tested at a concentration of lOμM and the inhibition expressed as % control value at this concentration (see Table 1, column 2). Subsequent determinations of the effects of 0.01-30 μM compound permitted estimation of the maximum inhibition attainable under these conditions (see Table 1, column 3); maximal inhibition close to 100%) could be achieved following longer incubation with the compounds. Such inhibitors also show activity in an intact cell system in which conversion of [*4C]- L-arginine to [**4C]-citrulline is measured in brain slices stimulated with veratrine.
SUBSTITUTE SHEET TABLE 1
Pterin-site Inhibitors of Neuronal NO Synthase
SUBSTITUTE SHEET Example 7:
In vitro tests of 7-nitroindazole activity
Nitric oxide synthase (NOS) activity was determined in vitro by the method of Dwyer et al., Biochem. Biophys. Res. Commun. 1991. 176, 1 136-1 141. Mice (male. LACA, 28-32 g) were killed by cervical dislocation. Cerebella were removed, homogenized (1 :10 w/v in 20mM tris buffer containing 2mM EDTA, pH. 7.4) and aliquots (25μl) incubated (37°C) with L-arginine (120nM) containing 0.5 μCi [3H]- arginine (specific activity 62 Ci mmol"-*), NADPH (0.5mM) and CaCb (0.75mM). Incubations also contained (a) 7-nitroindazole (MIM Research Chemicals Ltd.) in 0.5% w/v sodium carbonate solution (dissolution was effected by heating to 80°C and cooling when the 7-nitroindazole remained in solution), (b) for comparative puposes. L-N^-nitoarginine methyl ester (L-NAME) or L-N^-monomethyl arginine (L-NMMA) in distilled water, or, (c) as control, an equal volume (5μl) of 0.5% (w/v) sodium carbonate or distilled water. Final incubation volume was 105 μl. After 15 minutes the reaction was stopped by addition of 3 ml HEPES buffer (20mM containing 2 mM EDTA, pH 5.5. and pHJ-citrulline produced was separated by cation exchange chromatography on 0.5 ml columns of Dowex AG50- W8 Na4" form. [3H]-Citrulline was quantitated by liquid scintillation spectroscopy of duplicate 1 ml aliquots of the flow-through.
In some experiments mice were injected i.p. with 7-nitroindazole (25 mg kg"-*) or L- NAME (50mg kg"-*) and killed 15 minutes thereafter. Cerebella were removed, homogenized and NOS activity determined as described above.
It was found the 7-nitroindazole potently inhibited mouse cerebellar NOS in vitro (IC50 0.47 ± 0.0 lμM). For comparison, it was 1.8 times more potent than L-NAME (IC50 0.87 ± 0.02μM) and 5 times more potent than L-NMMA (IC50 2.37 ± 0.03μ M), the detailed results being presented in Figure 2. The results shown give the mean ± s.e. mean, n = 6 (statistical anlaysis carried out by Student's unpaired t test). Where no error bar is indicated the error lies within the dimensions of the symbol. In separate experiments, administration of 7-nitroindazole (25 mg kg"' , i.p.) decreased mouse cerebella NOS activity measured 15 minutes thereafter by over 55% (3.9 ± 0.06 nmol citrulline mg"*- protein 15 min" ** , cf. 9J ± 0.26 arachis oil- injected controls, n = 6, PO.01 ). For comparison, a higher dose of L-NAME (50 mg kg" produced only 46.2 ± 1.6% inhibition of this enzyme under indentical
SUBSTITUTE SHEET condition (4.46 ± 0.012 pmol citrulline mg"*- protein 15 min"' . cf. 8.33 ± 0J5. saline-injected controls, n = 6. PO.01).
Example 8:
In vivo tests of 7-nitroindazole activity
Anti-nociceptive activity of 7-nitroindazole (10-50 mg kg "') administered i.p. to mice as a suspension in arachis oil produced by sonication was determined by the formalin-induced hindpaw licking assay as descrived by Moore et al., British Journal of Pharmacology, 1991, 102, 198-202. Control animals received 10ml kg'-- of arachis oil or saline (0.9% w/v NaCl). This test shows hindpaw licking time (seconds) in the early (0-5 minutes) and late (15-30 minutes) phases on injection of lOμl formalin (5% v/v) administered 15 minutes after the 7-nitroindazole.
In separate experiments, again described by Moore et al (ibid), the blood pressure of urethane-anaesthetized (10 g kg"*) mice was monitored for 45 minutes after i.p. administration of 7-nitroindazole.
7-Nitroindazole (10, 25 and 50 mg kg"-*) produced a dose-related inhibition of late phase formalin-induced hindpaw licking without influencing the early phase response. The detailed results are presented in Figure 3 where open columns indicate the early phase (0.5 minutes) and hatched columns the late phase (15-30 minutes) hindpaw licking times. The mean ± s.e. mean is shown (statistical analysis by Student's unpaired t test), n = 6-12. **P<0.01. The control animals, identified by C. are those which received 10 ml kg"' arachis oil which, alone, did not influence hindpaw licking time. (The saline-injected mice gave an early phase value of 89.8 ± 7.0 seconds and a late phase value of 150.7 ± 1 1.5 seconds, n =15). The ED50 for the anti-nociceptive effect was 26 mg kg"' (equivalent to 159.5 μmol kg"').
Administration of 7-nitroindazole (25 and 80 mg kg"') did not increase mean arterial pressure (MAP) over the 45 minute experimental period (e.g. 25 mg kg"', 47.4 ± 5.1 mmHg, cf. 51.6 ± 4.4 mmHg, n = 4, before 7-nitroindazole administration. 80 mg kg"' , 43.9 ± 5.3 mmHg. cf. 49.5 ± 2.9 mmHg. n = 4. before 7- nitroindazole administration). In control experiments, i.p. administration of arachis oil failed to alter MAP.
Example 9:
SUBSTITUTE SHEET In vitro and in vivo tests of other indazoles
The procedure of Example 7 was repeated for 7-nitroindazole and other indazoles but using rat cerebella. The IC50 values so obtained for inhibition of rat cerebella nitric oxide synthase (NOS) for various indazoles are shown in Table 2 below.
The procedure of Example 8 was repeated for 7-nitroindazole and other indazoles. The percentage inhibition of formalin-induced licking in the late phase following the administration of 50 mg kg"' i.p. of the indazoles is shown in Table 2 below. For the compound 5-nitroindazole. where an asterisk is shown, a pronounced sedative effect was produced which interfered with the determination of the anti-nociceptive effect so that it could not be quantitated. The other indazoles did not exhibit an overtly sedative effect.
Table 2
Example 10:
Formulation of medicaments
(A) Tablets of the following composition are prepared:
mg/tablet
7-nitroindazole (micronised) 250 'Avicel' (microcrystalline cellulose) 38 polyvinylpyrrolidone j
SUBSTITUTE SHEET alginic acid 6 magnesium stearate 3
The 7-nitroindazole is mixed with 'Avicel' and polyvinylpyrrolidone is added, dissolved in sufficient industrial methylated spirits (74° OP) to produce a mass suitable for granulating. The mass is granulated through a 20 mesh sieve and the resultant granules are dried at a temperature not exceeding 50°C. The dried granules are passed through a 20 mesh sieve and the alginic acid and magnesium stearate are then added and mixed with the granules. The produce is compressed into tablets each weighing 300 mg on 3/8 inch flat bevelled edge divided punches.
(B) Tablets of the following composition are prepared:
mg/tablet
7-nitroindazole (micronised) 250 lactose (300 mesh) 134 maize starch 4 gelatine 8 magnesium stearate 4
The tablets are prepared by essentially the same procedure as described in (A) and are compressed at a tablet weight of 400mg on 7/16 inch fait bevelled punches.
(C) Tablets of the following composition are prepared:
mg/tablet
7-nitroindazole (micronised) 250 lactose (300 mesh) 19 maize starch 15 gelatine 10 magnesium stearate 6
The 7-nitroindazole is mixed with lactose and half the total quantity of maize starch required, and a 5% solution of gelatine in water is added to the mass. The product is granulated through a 16 mesh sieve, and the resultant granules are dried to constant weight
SUBSTITUTE SHEET at a temperature not exceeding 50°C. The dried granules are passed through a 20 mesh sieve and mixed with magnesium stearate and the remainder of the maize starch. The product is compressed at a 300 mg tablet weight on 3/8 inch flat bevelled edge divided punches.
SUBSTITUTE SHEET

Claims

1. Use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase.
2. Use of a compound according to Claim 1, wherein the compound is one of formula (I A), formula (IC) or a structural analogue of tetrahydrobiopterin or salts thereof
Wherein R1 and R2 are the same or different and each is hvdrogen or a C 1 -4 alkvl group or N R1 R2 forms a 5- or 6-membered heterocyclic group ' v \
wherein T is oxygen, CH2 or nitrogen substituted by hydrogen or C1 -4 alkyl, and v and w are the same or different and each is 1 or 2 provided the sum of v and w is 3 or 4; X is nitrogen or CH; Y is nitrogen, CH or CNH2; D is a group S(O)x wherein x is 0, 1 or 2, a C 1 -4 alkylene chain, or a C2 -4 alkenylene or alkynylene chain: d is 0 or 1 : Ar is a monocyclic or bicyclic ring system which may contain one or two heteroatoms and which contains at least one aromatic ring; R3 represents hydrogen or one to three substituents on the ring system Ar which may be the same or different and are chosen from halo, N R5 R6 wherein R5 and R6 are independently selected from hydrogen or S(O)x' R7 wherein x' is 0, 1 or 2 and R7 is C 1 -4 alkyl; nitro. cyano. a C 1 -4 carboxcylic acid group or an ester thereof. C 1 -4 alkyl optionally substituted by one to three halo atoms; phenyl or a group -(A)mR8 wherein A represents oxygen. S(O)n wherein n is 0. 1 or 2, or N R9 wherein R9 is hydrogen or C 1 -4 alkyl optionally substituted by halo and m is 0 or 1 , and R8 is hydrogen, or C 1 -4 alkyl or phenyl each optionally substituted by one to three halo atoms; R4 is hydrogen. C 1 -4 alkyl. hydroxy. halo, trifluoromethyl or a group N R10 R11 wherein R10 and R11 are the same or different and each is hydrogen or C 1 -4 alkyl, or N R10 R11 forms a 5- or 6- membered heterocyclic group optionally substituted by a C 1 -4 alkyl group or R4 represents a C 1 -2 alkylene group linking the heterocyclic ring to Ar; R13, R14, R15 and R16 are each separately selected from hydrogen, halo, haloalkyl, formyl, carboxy. sulpho, ,yano. nitro, CO R18 and +NR1 8 R19 R20, wherein R18, R19 and R20 are each separately alkyl, aralkyl or aryl groups and R17 is selected form hydrogen, halo, haloalkyl, formyl, carboxy, sulpho, cyano, nitro, hydroxy, alkoxy, alkyl, COR18, NHCOR18 and +NR18R19R20 groups, wherein R18, R19 and R20 are each separately alkyl aralkyl or aryl groups.
3) Use of a compound of formula (IA) according to Claim 2. which is a compound of formula (II)
or a salt thereof, wherein R1, R2,X,Y,R4 are as hereinbefore defined, Ar' is a monocyclic or bicyclic ring system containing at least one aromatic ring, and R3 ' represents hydrogen or one to three substituents which may be the same or different and are chosen from halo, amino, nitro, cyano, a C 1 -4 carboxylic acid group or an ester thereof, a group -(A)mR8' wherein A and m are as hereinbefore defined and R8' is C 1 -4 alkyl optionally substituted by halo.
4) Use of a compound of formula (IA) according to Claim 2. which is a compound of formula (III)
or a salt thereof wherein D, d, Ar, R3 , R1 , R2 , X and R4 are as hereinbefore defined.
5. Use of a compound according to Claim 4. wherein the compound is selected from 2, 4-diamino-5-(3, 4-dichlorophenyl)pyrimidine
2, 4-diamino-5-(4-methoxyphenyl)pyrimidine
2, 4-diamino-5-(4-methylphenyl)pyrimidine
2, 4-diamino-5-(4-chlorophenyl)pyrimidine
2, 4-diamino-5-(3-chlorophenyl)pyrimidine
2, 4-diamino-5-(2, 4-dichlorophenyl)pyrimidine
2,4-diamino-5-(3-trifluoromethylphenyl)pyrimidine
2,-4-diamino-5-(3-bromophenyl)pyrimidine
2,4-diamino-5-(3-methylphenyl)pyrimidine
2,4-diamino-5-(3,4-methylenedioxyphenyl)pyrimidine
2,4-diamino-5-(3,4-ethylenendioxyphenyl)pyrimidine
or a salt thereof.
6. Use of a tetrahydrobiopterin analogue according to Claim 2 which is a compound of formula (IB)
wherein R12 is hydrogen, halo. C 1- 4 alkyl optionally substituted by halo or alkoxy.
7. Use of a compound of formula (IC) according to Claim 2, wherein R13, R14, R15, R16 and R17 are independently selected from hydrogen, nitro or halo.
8. Use according to Claim 1 for the treament of cerebral ischemia.
9. Use according to Claim 1 for the treatment of CNS trauma.
10. Use according to Claim 1 for the treatment of AIDS dementia.
1 1. Use according to Claim 1 for the treatment of epilepsy.
12. Use according to Claim 1 for the treatment of chronic neurogenerative disease or chronic pain.
13. Use according to Claim 1 for the treatment of schizophrenia.
14 Use according to Claim 1 for the treatment of conditions in which non-adrenegic non-cholinergic nerve may be implicated.
15. Use according to Claim 1 as an analgesic.
16. Use according to Claim 1 for the treatment of acute neurodegenerative diseases.
17. A compound of formula (IA), (IB) or (IC) or a salt thereof for use in medicine, with the proviso that R12 is not hydrogen, and that R14 and R15 are not independently selected from hydrogen, nitro or carboxy when R13, R16 and R17 are each hydrogen.
18. A novel compound of formula (IA), (IB) or (IC) or a salt thereof as hereinbefore defined.
19. A compound according to Claim 18 which is selected from:
2,4-diamino-5-(3-trifluoromethylphenyl)pyrimidine
2,-4-diamino-5-(3-bromophenyl)pyrimidine
2,4-diamino-5-(3-methylphenyl)pyrimidine
2,4-diamino-5-(3,4-methylenedioxyphenyl)pyrimidine
2,4-diamino-5-(3,4-ethylenendioxyphenyl)pyrimidine
2,4-diamino-6-(4-methoxyphenyl)pyrimidine
2,4-diamino-6-(3,4-dimethoxyphenyl)pyrimidine
2,4-diamino-5-(2-(4-methylphenyl)ethyl)pyrimidine
2,4-diamino-5-(4-methylphenylethynyl)pyrimidine
2,4-diamino-5-phenylethynylpyrimidine
2,6-diamino-3-(2,4,5-trichlorophenyl)pyridine
2,6-diamino-3-(4-methoxyphenyl)pyridine
2,6-diamino-3-(2-naphthyl)pyridine 2,6-bis(acetamido)-3-(3,4-dimethoxyphenyl)pyridine
2,6-diamino-3-(3,4-dimethoxyphenyl)pyridine
1-amino-2, 4-diaza-5, 6-dihydro-9-methoxy-3-(4-methyl-1-piperazinyl)phenanthrene
4-amino-9, 10-dihydro-7-methoxy-2-(4-methyl-1-piperazinyl)benzo[f]quinazoline
2-amino-5-((-naphthyl)pyrimidine
2-amino-5-(4-methoxyphenyl)pyrimidine
2-(4-methylpiperazinyl)-5-(2-naphthyl)pyrimidine
5-(3,4-dimethoxy)-2-(4-methyl-1-piperazinyl)pyrimidine
5-(1,3-benzo[d]dioxol-5-yl)-2-(4-methylpiperazin-1-yl)pyrimidine
5-(1,4-benzodioxan-6-yl)-2-(4-methylpiperazin-1-yl)pyrimidine
5 -(3 ,4-dichlorophenyl)-2-(4-methylpiperazinyl)pyrimidine
2,4-diamino-5-( 3-thienyl)pyrimidine
2,4-diamino-5-( 3 ,5-dimethoxyphenyl)pyrimidine
2,4-diamino-5-(2,5-dimethoxyphenyl)pyrimidine
2,4-diamino-5-biphenylpyrimidine
2,4-diamino-5-(3,5-bis(trifluoromethyl)phenyl)pyrimidine
2,4-diamino-5-(3,5-dichlorophenyl)pyrimidine
2,4-diamino-5-(2,5-dibromo-4-chlorophenyl)pyrimidine
2,4-diamino-5-(4-chloro-3-methanesulphonamidophenyl)pyrimidine
2,4-diamino-5-(4-methoxy-3-methylphenyl)pyrimidine
2,4-diamino-5-(4-trifluoromethylphenyl)pyrimidine
2,4-diamino-5-(4-trifluoromethoxyphenyl)pyrimidine
2,4-diamino-5-(3-amino-4-chlorophenyl)pyrimidine
2,4-diamino-5-( 3-aminophenyl)pyrimidine
2,4-diamino-5-(4-chloro-3-nitrophenyl)pyrimidine
2,4-diamino-5-(3-chloro-4-hydroxyphenyl)pyrimidine
2,4-diamino-5-(3-fluorophenyl)pyrimidine
2,4-diamino-5-(3-trifluoromethoxyphenyI)pyrimidine
2,4-diamino-5-(3-bromo-4-methoxyphenyl)pyrimidine
2,4-diamino-5-(3-fluoro-4-methoxyphenyl)pyrimidine
2,4-diamino-5-(3-chloro-4-methoxyphenyl)pyrimidine
2,4-diamino-5- (3-chloro-4-fluorophenyl)pyrimidine
2,4-diamino-5-(4-chlorophenyl)pyrimidine
20. A pharmaceutical formulation which comprises a compound which binds at the tetrahydrobiopterin site of NO synthase according to Claim 1, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients.
21. A process for the preparation of the novel compounds according to Claim 17. which comprises:
(a) for a compound of formula (IA)
(i) when X is nitrogen, by the cyclisation of a compound of the formula (IV)
wherein R21 is cyano or CO R23 wherein R23 is hydroxy, C1 -4 alkoxy or hydrogen and R22 is oxo or a group C u wherein L is a leaving group; with amino guanidine or guanidine respectively.
(ii) when R 1 and R2 are hydrogen the removal of one or more protecting groups
from NR1R2 and optionally from R4, when it is desired that R4 is NH2.
(iii) by the conversion of one compound of the formula (IA) to a further compound of the formula (IA), for example when R1 and/or R2 are C1 -4 alkyl the alkylation of the corresponding compound wherein R1 and/or R2 are hydrogen; or when R1 and R2 are hydrogen, the amination, or chlorination and subsequent amination. of a compound of the formula (V):
wherein Q is chloro or bromo, preferably chloro. or hydroxy respectively and R4' is hydrogen, methyl, hydroxy, trifluoromethyl or halo. (iv) when X is CH and Y is a group CH or CNH2 the reaction of a compound of the formula (VI): /
or a suitably protected derivative thereof, wherein R24 is hydrogen or NH2 with benzene boronic acid or benzene boronic acid substituted so as to give the desired substituent R1 1 in the compound of the formula (IA) so formed, followed by the removal of any protecting groups;
(b) for a compound of formula (IB), the reduction of the corresponding 8-oxide; and
(c) for a compound of formula (IC), the reaction of O-methylacetanilide containing the appropriate substituents or substituents covertible thereto.
22. A process which comprises :-
(i) the reaction of a compound of formula (VIII)
or a suitably protected derivative thereof wherein R1, R2, R4, X and Y are as hereinbefore defined, with iodine monochloride, to give a compound of formula (VII)
(ii) the reaction of a compound of formula (VII) as hereinbefore defined with a compound of formula R3-Ar-(D)d -B(OH)2 wherein R3 , Ar, D and d are as hereinbefore defined to give a compound of formula (IA) as hereinbefore defined.
EP94902868A 1992-12-18 1993-12-15 Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors Withdrawn EP0674627A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929226377A GB9226377D0 (en) 1992-12-18 1992-12-18 Pharmaceutical compositions
GB9226377 1992-12-18
GB9303221 1993-02-18
GB939303221A GB9303221D0 (en) 1993-02-18 1993-02-18 Nitric oxide synthase inhibitors
PCT/GB1993/002556 WO1994014780A1 (en) 1992-12-18 1993-12-15 Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors

Publications (1)

Publication Number Publication Date
EP0674627A1 true EP0674627A1 (en) 1995-10-04

Family

ID=26302179

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94902868A Withdrawn EP0674627A1 (en) 1992-12-18 1993-12-15 Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors

Country Status (6)

Country Link
EP (1) EP0674627A1 (en)
JP (1) JPH08504798A (en)
AU (1) AU5704594A (en)
IL (1) IL108075A0 (en)
MX (1) MX9308199A (en)
WO (1) WO1994014780A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557113A1 (en) 2011-08-12 2013-02-13 Schneider Electric Industries SAS Flame-retardant material comprising a biopolymer

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897912A1 (en) * 1993-10-21 1999-02-24 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
ES2151055T3 (en) * 1994-03-10 2000-12-16 Searle & Co DERIVATIVES OF L-N6- (1-IMINOETIL) LISINA USEFUL AS INHIBITORS OF NITRIC OXIDE SYNTHESA.
DE4418097A1 (en) * 1994-05-24 1995-11-30 Cassella Ag Use of tetrahydropteridine derivatives as inhibitors of NO synthase
DE4418096A1 (en) * 1994-05-24 1995-11-30 Cassella Ag Use of pteridine derivatives as inhibitors of NO synthase
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
WO1996018617A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
AU712315B2 (en) * 1995-04-20 1999-11-04 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
US5830917A (en) * 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) * 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
FR2745812B1 (en) * 1996-03-08 1998-05-07 Hoechst Lab DIBENZO (C, F) AZONINES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATIONS
ES2214604T3 (en) * 1996-03-29 2004-09-16 Pfizer Inc. DERIVATIVES OF 6-PHENYLPIRIDIL-2-AMINA.
HN1997000027A (en) 1996-12-06 1997-06-05 Pfizer Prod Inc DERIVATIVES OF 6-PHENYL PIRIDIL - 2 AMINE
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
KR100460399B1 (en) * 1997-02-10 2004-12-08 화이자 프로덕츠 인코포레이티드 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6489323B1 (en) 1998-06-10 2002-12-03 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
US6552052B2 (en) 1998-06-10 2003-04-22 Monsanto/G.D. Searle Pyrrolo[2,1-c][1,2,4] thiadiazoles and Pyrollo[2,1-c][1,12,4]oxadiazoles useful as nitric oxide synthase inhibitors
FR2784678B1 (en) * 1998-09-23 2002-11-29 Sod Conseils Rech Applic NOVEL N- (IMINOMETHYL) AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19944767A1 (en) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituted 4-aminopteridines, process for their preparation and their use as medicines
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
NZ520813A (en) 2000-03-24 2004-05-28 Pharmacia Corp Amidino compounds useful as nitric oxide synthase inhibitors
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR034120A1 (en) 2000-04-13 2004-02-04 Pharmacia Corp HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-4,5, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOUND AND SUCH COMPOSITION IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO INHIBIT OR MODULATE NITRIC ACID SYNTHESIS
AR030416A1 (en) 2000-04-13 2003-08-20 Pharmacia Corp HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-3,4, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF SYNTHETIC NITRIC OXIDE
AR032318A1 (en) 2000-04-13 2003-11-05 Pharmacia Corp HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-5,6; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF NITRICAL SYNTHEASE OXIDE
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6956131B2 (en) 2000-04-13 2005-10-18 Pharmacia Corporation 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
JP2004501083A (en) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド Pyrazole for inhibiting protein kinases
ATE469132T1 (en) 2000-07-24 2010-06-15 Krenitsky Pharmaceuticals Inc SUBSTITUTED 5-ALKINYL-PYRIMIDINES WITH NEUROTROPHIC ACTION
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
KR100406634B1 (en) * 2001-03-12 2003-11-20 주식회사 엘지생명과학 3,5-Diaminoindazole derivatives, their preparation and their use as inhibitors for cyclin dependent kinases
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
KR101286569B1 (en) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 Novel medicaments
EP2402324A1 (en) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazines
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd Pharmaceutical composition
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
KR20110041536A (en) 2008-07-29 2011-04-21 베링거 인겔하임 인터내셔날 게엠베하 5-alkynyl-pyrimidines
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8618111B2 (en) 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
CN103804312B (en) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 Aza cyclic cpds and its production and use
JP2021512946A (en) * 2018-02-05 2021-05-20 ユニヴェルスィテ・ドゥ・ストラスブール Compounds and compositions for treating pain
BR112021026837A2 (en) 2019-08-06 2022-02-22 Domain Therapeutics 5-Heteroaryl-pyridin-2-amine compounds as ff neuropeptide receptor antagonists
GB202006076D0 (en) * 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors
US20220289686A1 (en) * 2021-03-09 2022-09-15 Washington University Compositions of nrf2 inhibiting agents and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (en) *
FR7631M (en) * 1968-08-13 1970-01-26
US3843678A (en) * 1971-03-15 1974-10-22 Tenneco Chem Process for the production of substituted indazoles
FR2265739B1 (en) * 1974-03-29 1976-12-17 Ugine Kuhlmann
US3988347A (en) * 1974-09-09 1976-10-26 Tenneco Chemicals, Inc. Process for the preparation of substituted indazoles
DK426083A (en) * 1982-09-20 1984-03-21 Wellcome Found PTERINES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE
DE3786256T2 (en) * 1986-12-02 1993-10-07 British Tech Group ANTIFOLATE AGENT.
FI895821A0 (en) * 1988-12-07 1989-12-05 Wellcome Found PHARMACEUTICAL ACTIVE CNS FOERENINGAR.
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9414780A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557113A1 (en) 2011-08-12 2013-02-13 Schneider Electric Industries SAS Flame-retardant material comprising a biopolymer
US8927655B2 (en) 2011-08-12 2015-01-06 Schneider Electric Industries Sas Flame-retardant material comprising a biopolymer

Also Published As

Publication number Publication date
AU5704594A (en) 1994-07-19
JPH08504798A (en) 1996-05-21
MX9308199A (en) 1995-01-31
WO1994014780A1 (en) 1994-07-07
IL108075A0 (en) 1994-04-12

Similar Documents

Publication Publication Date Title
EP0674627A1 (en) Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US7173033B2 (en) Nitrogen-containing heterocyclic compound
US5958931A (en) Phenyl-substituted 5H-thiazolo 3,2-A!pyrimidine derivative glutamate receptor antagonists
US4663325A (en) 1-(2,3,4-tri-methoxybenzyl)-4[bis(4-fluorophenyl)methyl] piperazines are useful for treating cerebrovascular disease
US5589477A (en) Pyrimidine derivatives and drugs
TW200808807A (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
DE10057751A1 (en) New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
CZ281070B6 (en) Substituted 5-arylpyrimidine, process of its preparation and pharmaceutical preparation containing thereof
SK168499A3 (en) 3-substituted 3,4 dihydro-thieno[2,3-d]pyrimidine derivatives and production and use of the same
US3399201A (en) Aminoalkyl-ethano-anthracenes
DD229990A5 (en) PROCESS FOR PREPARING NEW 2-PIPERAZINO PTERIDINE
NZ204885A (en) Heteroaryl-substituted aminomethyl benzene derivatives and pharmaceutical compositions
DE60004671T2 (en) NEW PIPERAZINYLALKYLTHIOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
EP0047536A2 (en) Substituted propylamines
US3983239A (en) Hexahydro-γ-carboline derivatives and their salts
NZ229144A (en) Substituted pyrimidinedione derivatives and pharmaceutical compositions, and 1-(1-piperazinyl) isoquinoline as an intermediate reagent
AU749539B2 (en) 3-substituted 3,4,5,7-tetrahydro-pyrrolo3&#39;,4&#39;:4,5 thieno2,3-dpyrimidine derivatives, their preparation and use as 5HT antagonists
DK156722B (en) ANALOGY PROCEDURE FOR PREPARING 2-PIPERAZINOPYRIMIDINE DERIVATIVES
SK3872000A3 (en) 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHODì (54) FOR PRODUCING THE SAME, AND THEIR USE
DK162220B (en) TRICYCLIC PYRIDAZINE DERIVATIVES WHICH ARE AGONISTS OF CHOLINERGE RECEPTORS, PROCEDURES FOR THE PREPARATION OF THE DERIVATIVES, AND MEDICINAL PRODUCTS
SU927111A3 (en) Process for producing oxime-esters or their salts
EP1603888B1 (en) 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazoline-4-yl) acetic acids as anti-viral agents, especially against cytomegalo viruses
US5728692A (en) Methotrexate derivative
CA1203537A (en) Process for the preparation of 2-piperazinopyrimidine derivatives
HUT77130A (en) [1,2,4]triazolo[1,5-b]pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19970211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970624